secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001437749-24-006817
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera Q4 net loss $4.5M; cash $9.4M; Niyad study enrollment imminent; $26M committed
--------------------------------------------------------------------------------

- Net loss from continuing ops of $4.5M ($0.25/sh) vs $5.9M ($1.00/sh) in Q4 2022; revenues $0.3M.
- Cash and investments $9.4M at Dec 31, 2023; senior debt fully repaid in Q2 2023.
- Jan 2024: $26M committed capital — $8M DSUVIA royalty monetization with Xoma + $18M equity from two investors.
- First patient enrollment in NEPHRO CRRT registrational study expected Q1 2024; PMA submission targeted by end 2024.
- Company rebranded from AcelRx to Talphera in Jan 2024; now trades as TLPH on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/0001437749-24-006817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/acrx20240305_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-006817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer